JP2023098947A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2023098947A5 JP2023098947A5 JP2023061595A JP2023061595A JP2023098947A5 JP 2023098947 A5 JP2023098947 A5 JP 2023098947A5 JP 2023061595 A JP2023061595 A JP 2023061595A JP 2023061595 A JP2023061595 A JP 2023061595A JP 2023098947 A5 JP2023098947 A5 JP 2023098947A5
- Authority
- JP
- Japan
- Prior art keywords
- use according
- antagonist
- composition
- fibrosis
- senescent cells
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| EP17382417.8 | 2017-06-29 | ||
| EP17382417.8A EP3421607A1 (en) | 2017-06-29 | 2017-06-29 | Identification and elimination of damaged and/or senescent cells |
| JP2019572038A JP2020525021A (ja) | 2017-06-29 | 2018-06-29 | 損傷および／または老化細胞の同定および排除 |
Related Parent Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2019572038A Division JP2020525021A (ja) | 2017-06-29 | 2018-06-29 | 損傷および／または老化細胞の同定および排除 |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2023098947A JP2023098947A (ja) | 2023-07-11 |
| JP2023098947A5 true JP2023098947A5 (enExample) | 2024-03-25 |
Family
ID=59315550
Family Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2019572038A Pending JP2020525021A (ja) | 2017-06-29 | 2018-06-29 | 損傷および／または老化細胞の同定および排除 |
| JP2023061595A Pending JP2023098947A (ja) | 2017-06-29 | 2023-04-05 | 損傷および／または老化細胞の同定および排除 |
Family Applications Before (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2019572038A Pending JP2020525021A (ja) | 2017-06-29 | 2018-06-29 | 損傷および／または老化細胞の同定および排除 |
Country Status (5)
| Country | Link |
|---|---|
| US (2) | US20200123607A1 (enExample) |
| EP (2) | EP3421607A1 (enExample) |
| JP (2) | JP2020525021A (enExample) |
| CA (1) | CA3068363A1 (enExample) |
| WO (1) | WO2019002581A1 (enExample) |
Families Citing this family (17)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN113365663B (zh) | 2018-08-30 | 2025-11-21 | 免疫生物公司 | 单链嵌合多肽和其用途 |
| KR20250160211A (ko) | 2018-08-30 | 2025-11-11 | 이뮤니티바이오, 인크. | 다중-사슬 키메라 폴리펩타이드 및 이의 용도 |
| AU2020294797B2 (en) | 2019-06-21 | 2025-12-18 | Immunitybio, Inc. | Multi-chain chimeric polypeptides and uses thereof |
| AU2021219720B2 (en) | 2020-02-11 | 2025-10-02 | Immunitybio, Inc. | Chromatography resin and uses thereof |
| JP2023513573A (ja) | 2020-02-11 | 2023-03-31 | エイチシーダブリュー バイオロジックス インコーポレイテッド | 加齢性および炎症性疾患を治療する方法 |
| CA3169243A1 (en) | 2020-02-11 | 2021-08-19 | HCW Biologics, Inc. | Methods of activating regulatory t cells |
| US12497462B2 (en) | 2020-04-29 | 2025-12-16 | Immunitybio, Inc. | Anti-CD26 proteins and uses thereof |
| US12024545B2 (en) * | 2020-06-01 | 2024-07-02 | HCW Biologics, Inc. | Methods of treating aging-related disorders |
| EP4431102A4 (en) * | 2021-11-10 | 2025-10-29 | Lifeceutix Co Ltd | Senescent Cell Elimination Compositions and Their Uses |
| CN114836508A (zh) * | 2021-12-08 | 2022-08-02 | 上海锐翌医学检验实验室有限公司 | 慢性阻塞性肺病标志微生物及其应用 |
| KR20240155337A (ko) | 2022-03-04 | 2024-10-28 | 리주베론 세네센스 테라퓨틱스 아게 | 항-pd-l2 항체 |
| JPWO2023238845A1 (enExample) * | 2022-06-07 | 2023-12-14 | ||
| CN115154611B (zh) * | 2022-06-23 | 2023-11-17 | 中山大学孙逸仙纪念医院 | 免疫检查点抑制剂与抗衰老药物联合在制备肿瘤治疗产品中的用途 |
| WO2024063109A1 (ja) * | 2022-09-20 | 2024-03-28 | 国立大学法人東京大学 | 老化細胞除去剤 |
| WO2024228599A1 (ko) * | 2023-05-04 | 2024-11-07 | 주식회사 라이프신약 | 노화세포 제거 또는 억제용 조성물 및 이의 용도 |
| WO2024249938A1 (en) * | 2023-05-31 | 2024-12-05 | Mayo Foundation For Medical Education And Research | Methods and materials for identifying and treating senescence/age-related diseases |
| WO2025051889A1 (en) * | 2023-09-06 | 2025-03-13 | Rejuveron Senescence Therapeutics Ag | Anti pd-l2 antibodies for use in treating fibrotic diseases |
Family Cites Families (10)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| GB8308235D0 (en) | 1983-03-25 | 1983-05-05 | Celltech Ltd | Polypeptides |
| US5225539A (en) | 1986-03-27 | 1993-07-06 | Medical Research Council | Recombinant altered antibodies and methods of making altered antibodies |
| WO1994004679A1 (en) | 1991-06-14 | 1994-03-03 | Genentech, Inc. | Method for making humanized antibodies |
| AU2005248958A1 (en) * | 2000-06-28 | 2006-02-02 | Brigham And Women's Hospital | PD-L2 molecules: novel PD-1 ligands and uses therefor |
| AU7309601A (en) * | 2000-06-28 | 2002-01-08 | Genetics Inst | Pd-l2 molecules: novel pd-1 ligands and uses therefor |
| AU2015214404B2 (en) * | 2014-02-04 | 2020-10-01 | Incyte Corporation | Combination of a PD-1 antagonist and an IDO1 inhibitor for treating cancer |
| WO2016134416A1 (en) * | 2015-02-23 | 2016-09-01 | The University Of Queensland | A method for assessing prognosis of lymphoma |
| ES2861352T3 (es) * | 2015-04-28 | 2021-10-06 | Bristol Myers Squibb Co | Tratamiento del melanoma positivo para PD-L1 utilizando un anticuerpo anti-PD-1 |
| MX389834B (es) * | 2015-06-24 | 2025-03-20 | Immodulon Therapeutics Ltd | Inhibidor del punto de regulacion y un mycobaterium de celula entera para uso en la terapia del cancer. |
| CA2995502A1 (en) * | 2015-09-21 | 2017-03-30 | Merck Sharp & Dohme Corp. | Antibody that binds to human programmed death ligand 2 (pd-l2) and uses thereof |
-
2017
- 2017-06-29 EP EP17382417.8A patent/EP3421607A1/en not_active Withdrawn
-
2018
- 2018-06-29 EP EP18735568.0A patent/EP3645746A1/en active Pending
- 2018-06-29 US US16/627,034 patent/US20200123607A1/en not_active Abandoned
- 2018-06-29 WO PCT/EP2018/067655 patent/WO2019002581A1/en not_active Ceased
- 2018-06-29 CA CA3068363A patent/CA3068363A1/en active Pending
- 2018-06-29 JP JP2019572038A patent/JP2020525021A/ja active Pending
-
2023
- 2023-04-05 JP JP2023061595A patent/JP2023098947A/ja active Pending
-
2024
- 2024-06-21 US US18/750,834 patent/US20240344128A1/en active Pending
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2023098947A5 (enExample) | ||
| Galsky et al. | Gemcitabine, cisplatin, and sunitinib for metastatic urothelial carcinoma and as preoperative therapy for muscle-invasive bladder cancer | |
| Khanna et al. | Ongoing clinical trials and treatment options for patients with systemic sclerosis–associated interstitial lung disease | |
| Kim et al. | Cyclophosphamide in dermatology | |
| JP2017522307A5 (enExample) | ||
| JP7142200B2 (ja) | ＭＡｄＣＡＭアンタゴニストの投与レジメン | |
| JP2017537090A5 (enExample) | ||
| JP2025176106A (ja) | Ｉｌ－２３及びｔｎｆアルファに対する抗体の併用療法による炎症性腸疾患の治療方法 | |
| Kuwana et al. | Nintedanib: New indication for systemic sclerosis-associated interstitial lung disease | |
| JP2014533279A5 (enExample) | ||
| JP2017514795A5 (enExample) | ||
| JP2017501167A5 (enExample) | ||
| JP2017537105A (ja) | 瘻孔を伴うクローン病の治療用ベドリズマブ | |
| JP2013531038A (ja) | 癌の治療のための低酸素活性化プロドラッグおよび血管新生阻害剤の投与方法 | |
| JP2017113019A5 (enExample) | ||
| JP2020511408A5 (enExample) | ||
| JP2017530163A5 (enExample) | ||
| JP2019533651A5 (enExample) | ||
| JP2019525948A5 (enExample) | ||
| KR20230098279A (ko) | Pdx 억제제 또는 독소루비신과 ahr 억제제의 조합 | |
| JP2014532648A5 (enExample) | ||
| WO2017165742A1 (en) | Methods of treating gastrointestinal immune-related adverse events in anti-ctla4 anti-pd-1 combination treatments | |
| JP2017527615A5 (enExample) | ||
| Novello et al. | Motesanib plus carboplatin/paclitaxel in patients with advanced squamous non–small-cell lung cancer: results from the randomized controlled MONET1 study | |
| CA3201519A1 (en) | Methods and compositions comprising a krasg12c inhibitor and a pd-l1 binding antagonist for treating lung cancer |